2024-01-16 10:51
(47 d 16:58 ago)

(edited by SMA on 2024-01-16 11:07)
Posting: # 23828
Views: 619

 New EMA product specific guidance (PSG) [BE/BA News]

Dear all

EMA has published two new PSGs:
  • Azacitidine powder for suspension for injection 25 mg/ml product-specific bioequivalence guidance (here)
  • Paliperidone palmitate depot suspension for injection (every 3 months) 175, 263, 350 and 525 mg product-specific bioequivalence guidance (here)
Consultations open until 2024-04-30

India/United Kingdom,
2024-01-17 11:12
(46 d 16:36 ago)

Posting: # 23830
Views: 488

 New EMA product specific guidance (PSG)

Thanks SMA for sharing.

Dear all, In Azacitidine powder for suspension for injection PSG, I am having a small question.

For biowaiver it is mentioned- "Equivalent particle size distribution as demonstrated by showing average equivalence for D10, D50, D90 and span within an acceptance range of 15% for the ratio of geometric means between test and reference products (i.e., 85.00–117.64%)."
But it also mentions: "At least 3 batches of the test and reference product should be included in the comparability studies. More batches may be needed in case of higher variability of the reference product results."

So in case of higher variability in reference product result for PSD, the ratio should be limited to 85.00–117.64%?

UA Flag
 Admin contact
22,919 posts in 4,807 threads, 1,643 registered users;
31 visitors (0 registered, 31 guests [including 6 identified bots]).
Forum time: 03:49 CET (Europe/Vienna)

The analysis of variance is not a mathematical theorem,
but rather a convenient method of arranging the arithmetic.    R.A. Fisher

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz